论文部分内容阅读
目的:观察已酮可可碱(Trental)对2型糖尿病患者血液凝固相关指标的变化。方法:观察了40例2型糖尿病患者应用已酮可可碱4周后血小板聚集率(PAgR)、血栓素B2(TXB2)、6-酮-前列腺素F1α(6-keto-PGF1α)、血浆组织纤溶酶原激活物(tPA)、血浆纤溶酶原激活物抑制剂(PAI-1)及血粘度的变化。结果:用药后PAgR、TXB2、PAI-1及血粘度明显下降,而6-keto-PGF1α及tPA明显升高。结论:提示已酮可可碱可作用于细胞水平及细胞膜流动性的改变,以改善糖尿病的血液高凝状态
Objective: To observe the changes of blood coagulation related indexes in patients with type 2 diabetes treated with pentoxifylline (Trental). Methods: 40 patients with type 2 diabetes mellitus were treated with pentoxifylline 4 weeks after the platelet aggregation rate (PAgR), thromboxane B2 (TXB2), 6-keto-prostaglandin F1α (6-keto-PGF1α), plasma tissue (TPA), plasma plasminogen activator inhibitor (PAI-1) and blood viscosity changes. Results: After treatment, PAgR, TXB2, PAI-1 and blood viscosity decreased significantly, while 6-keto-PGF1α and tPA were significantly increased. Conclusion: It is suggested that pentoxifylline can act on cellular level and cell membrane fluidity change to improve the blood hypercoagulability state of diabetes